BD's Covera Vascular Stent Approved for Patients With End-Stage Renal Disease


March 14, 2019—BD (Becton, Dickinson and Company) has received FDA premarket approval of the Covera vascular covered stent for patients with end-stage renal disease who are on hemodialysis.

According to the company, the Covera device is approved in the United States for use in the treatment of stenoses in native (nonstented) fistulae. Covera was designed to address challenging lesions in the arteriovenous access circuit. It is available in both a flared and a straight configuration to allow for precise sizing and apposition to the vessel wall, and it includes an easy-to-use thumbwheel delivery system.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.